新冠康复患者的肺纤维化：问题与潜在管理
Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management.
作者信息
Kayarat Bhavana, Khanna Puneet, Sarkar Soumya
机构信息
Department of Anaesthesia, Pain Medicine and Critical Care, AIIMS, New Delhi, India.
出版信息
Indian J Crit Care Med. 2021 Feb;25(2):242-244. doi: 10.5005/jp-journals-10071-23733.
Abstract
B, Khanna P, Sarkar S. Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management. Indian J Crit Care Med 2021;25(2):242-244.
摘要
B、坎纳P、萨卡尔S。新冠康复患者的肺纤维化：问题与潜在管理。《印度重症监护医学杂志》2021年；25(2)：242 - 244。
相似文献
1
Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management.新冠康复患者的肺纤维化：问题与潜在管理
Indian J Crit Care Med. 2021 Feb;25(2):242-244. doi: 10.5005/jp-journals-10071-23733.
2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: Is Sequela the Bigger Threat?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行：后遗症是更大的威胁吗？
Indian J Crit Care Med. 2021 Feb;25(2):245-246. doi: 10.5005/jp-journals-10071-23734.
3
Superadded Coinfections and Antibiotic Resistance in the Context of COVID-19: Where do We Stand?2019冠状病毒病背景下的叠加感染与抗生素耐药性：我们目前的情况如何？
Indian J Crit Care Med. 2021 Jun;25(6):699-703. doi: 10.5005/jp-journals-10071-23855.
4
Eyes Have It: From COVID-19 Perspective.
Indian J Crit Care Med. 2020 Nov;24(11):1139-1140. doi: 10.5005/jp-journals-10071-23644.
5
In Pursuit of Freedom from COVID-19 Awareness in India: An Infodemiological Analysis.在印度追求摆脱对新冠疫情的认知：一项信息流行病学分析
Indian J Crit Care Med. 2021 Apr;25(4):470-472. doi: 10.5005/jp-journals-10071-23780.
6
Post-COVID-19 Pulmonary Fibrosis: A Lifesaving Challenge.新冠后肺纤维化：一项拯救生命的挑战。
Indian J Crit Care Med. 2021 Jan;25(1):104-105. doi: 10.5005/jp-journals-10071-23709.
7
Respiratory Care for Severe COVID-19.重症新型冠状病毒肺炎的呼吸治疗
Indian J Crit Care Med. 2020 Jul;24(7):493-495. doi: 10.5005/jp-journals-10071-23509.
8
COVID-19-associated Pulmonary Cryptococcosis: A Rare Case Presentation.新型冠状病毒肺炎相关肺隐球菌病：1例罕见病例报告
Indian J Crit Care Med. 2022 Jan;26(1):129-132. doi: 10.5005/jp-journals-10071-24084.
9
COVID-19-associated Severe Multisystem Inflammatory Syndrome in Children with Encephalopathy and Neuropathy in an Adolescent Girl with the Successful Outcome: An Unusual Presentation.一名患有脑病和神经病变的青春期女孩出现与COVID-19相关的儿童严重多系统炎症综合征，预后良好：一种不寻常的表现。
Indian J Crit Care Med. 2020 Dec;24(12):1276-1278. doi: 10.5005/jp-journals-10071-23685.
10
Critical Care for COVID-19 Affected Patients: Position Statement of the Indian Society of Critical Care Medicine.新型冠状病毒肺炎（COVID-19）感染患者的重症监护：印度重症监护医学学会立场声明
Indian J Crit Care Med. 2020 Apr;24(4):222-241. doi: 10.5005/jp-journals-10071-23395.
引用本文的文献
1
A Chinese classical prescription Maimendong decoction in treatment of pulmonary fibrosis: an overview.中药经典方剂麦门冬汤治疗肺纤维化的概述
Front Pharmacol. 2024 May 9;15:1329743. doi: 10.3389/fphar.2024.1329743. eCollection 2024.
2
Pharmacological approaches to pulmonary fibrosis following COVID-19.新冠病毒感染后肺纤维化的药理学治疗方法。
Front Pharmacol. 2023 Jun 15;14:1143158. doi: 10.3389/fphar.2023.1143158. eCollection 2023.
3
Tocotrienol-Rich Fractions Offer Potential to Suppress Pulmonary Fibrosis Progression.富含生育三烯酚的馏分有望抑制肺纤维化的进展。
Int J Mol Sci. 2022 Nov 18;23(22):14331. doi: 10.3390/ijms232214331.
4
Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.吡非尼酮与新冠后肺纤维化：再次为现实目标而呼吁。
Inflammopharmacology. 2022 Dec;30(6):2017-2026. doi: 10.1007/s10787-022-01027-6. Epub 2022 Aug 31.
5
Potential "Therapeutic" Effects of Tocotrienol-Rich Fraction (TRF) and Carotene "Against" Bleomycin-Induced Pulmonary Fibrosis in Rats via TGF-β/Smad, PI3K/Akt/mTOR and NF-κB Signaling Pathways.生育三烯酚丰富部分（TRF）和类胡萝卜素对博来霉素诱导的大鼠肺纤维化的潜在“治疗”作用通过 TGF-β/Smad、PI3K/Akt/mTOR 和 NF-κB 信号通路。
Nutrients. 2022 Mar 5;14(5):1094. doi: 10.3390/nu14051094.
本文引用的文献
1
Lung fibrosis: an undervalued finding in COVID-19 pathological series.肺纤维化：COVID-19病理系列中一项被低估的发现。
Lancet Infect Dis. 2021 Apr;21(4):e72. doi: 10.1016/S1473-3099(20)30582-X. Epub 2020 Jul 28.
2
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.肺纤维化与 COVID-19：抗纤维化治疗的潜在作用。
Lancet Respir Med. 2020 Aug;8(8):807-815. doi: 10.1016/S2213-2600(20)30225-3. Epub 2020 May 15.
3
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.COVID-19 患者出院时的肺功能异常。
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.01217-2020. Print 2020 Jun.
4
Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study.医院获得性严重急性呼吸综合征的长期骨骼和肺部后果：一项前瞻性队列研究的15年随访
Bone Res. 2020 Feb 14;8:8. doi: 10.1038/s41413-020-0084-5. eCollection 2020.
5
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.尼达尼布治疗进行性纤维化间质性肺疾病。
N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
6
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis.mTORC1/4E-BP1 轴在纤维化过程中代表一个关键的信号节点。
Nat Commun. 2019 Jan 2;10(1):6. doi: 10.1038/s41467-018-07858-8.
7
Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients.抗氧化活性介导了吡非尼酮在特发性肺纤维化患者血清诱导的人肺动脉平滑肌细胞中的抗纤维化作用。
Oxid Med Cell Longev. 2018 Oct 21;2018:2639081. doi: 10.1155/2018/2639081. eCollection 2018.
8
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.重组人 Pentraxin 2 与安慰剂对特发性肺纤维化患者用力肺活量变化的影响：一项随机临床试验。
JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.
9
Follow-up chest radiographic findings in patients with MERS-CoV after recovery.中东呼吸综合征冠状病毒（MERS-CoV）患者康复后的胸部X线随访结果
Indian J Radiol Imaging. 2017 Jul-Sep;27(3):342-349. doi: 10.4103/ijri.IJRI_469_16.
10
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.特发性肺纤维化的新兴疗法，一种与年龄相关的进行性疾病。
Nat Rev Drug Discov. 2017 Oct 30;16(11):810. doi: 10.1038/nrd.2017.225.
Zotero 插件